Technical Analysis for ERYP - Erytech Pharma S.A.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical ERYP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | -1.78% | |
| Death Cross | Bearish | -1.78% | |
| Bollinger Band Squeeze | Range Contraction | -1.78% | |
| Narrow Range Bar | Range Contraction | -1.78% | |
| NR7 | Range Contraction | -1.78% | |
| Bollinger Band Squeeze | Range Contraction | -1.07% | |
| BB Squeeze + Lower Band Touch | Range Contraction | -1.07% | |
| Inside Day | Range Contraction | -1.07% | |
| Lower Bollinger Band Touch | Weakness | -1.07% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. | |
Get a Trading Sidekick!
- Earnings date: 05/07/2019
Erytech Pharma S.A. Description
Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death. The Company's subsidiary is Erytech Pharma, Inc in the USA which legal existence began in April 9, 2014.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Hematology Enzymes Antineoplastic Drugs Cancer Cell Leukemia Childhood Red Blood Cell Acute Lymphoblastic Leukemia Blood Cells Medicinal Product Asparaginase Childhood Cancer Medicinal Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.95 |
| 52 Week Low | 3.5 |
| Average Volume | 15,948 |
| 200-Day Moving Average | 8.11 |
| 50-Day Moving Average | 8.00 |
| 20-Day Moving Average | 7.05 |
| 10-Day Moving Average | 7.01 |
| Average True Range | 0.45 |
| ADX | 37.36 |
| +DI | 12.51 |
| -DI | 24.37 |
| Chandelier Exit (Long, 3 ATRs ) | 6.33 |
| Chandelier Exit (Short, 3 ATRs ) | 7.84 |
| Upper Bollinger Band | 7.42 |
| Lower Bollinger Band | 6.67 |
| Percent B (%b) | 0.31 |
| BandWidth | 10.65 |
| MACD Line | -0.28 |
| MACD Signal Line | -0.35 |
| MACD Histogram | 0.0654 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.29 | ||||
| Resistance 3 (R3) | 7.28 | 7.15 | 7.22 | ||
| Resistance 2 (R2) | 7.15 | 7.05 | 7.15 | 7.20 | |
| Resistance 1 (R1) | 7.03 | 6.99 | 6.96 | 7.03 | 7.18 |
| Pivot Point | 6.89 | 6.89 | 6.86 | 6.89 | 6.89 |
| Support 1 (S1) | 6.77 | 6.79 | 6.70 | 6.78 | 6.63 |
| Support 2 (S2) | 6.64 | 6.73 | 6.64 | 6.61 | |
| Support 3 (S3) | 6.52 | 6.64 | 6.59 | ||
| Support 4 (S4) | 6.52 |
